SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-20-291944
Filing Date
2020-11-13
Accepted
2020-11-12 20:42:03
Documents
9
Period of Report
2020-11-12
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d40620d8k.htm 8-K 37814
2 EX-2.1 d40620dex21.htm EX-2.1 533087
3 EX-10.1 d40620dex101.htm EX-10.1 57735
4 EX-99.1 d40620dex991.htm EX-99.1 21518
5 EX-99.2 d40620dex992.htm EX-99.2 24007
6 GRAPHIC g40620address.jpg GRAPHIC 12606
7 GRAPHIC g40620g63g20.jpg GRAPHIC 7312
8 GRAPHIC g40620g97w62.jpg GRAPHIC 6136
9 GRAPHIC g40620urovant.jpg GRAPHIC 10918
  Complete submission text file 0001193125-20-291944.txt   726837
Mailing Address 5281 CALIFORNIA AVENUE SUITE 100 IRVINE CA 92617
Business Address 5281 CALIFORNIA AVENUE SUITE 100 IRVINE CA 92617 949-226-6029
Urovant Sciences Ltd. (Filer) CIK: 0001740547 (see all company filings)

IRS No.: 000000000 | State of Incorp.: D0 | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-38667 | Film No.: 201308843
SIC: 2834 Pharmaceutical Preparations